Clinical trials: Solid Tumor, completed
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.
- Trial name
- NCT00046696
- Testing
- NM-3
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Genzyme, a Sanofi Company
Unspecified Adult Solid Tumor, Protocol Specific
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00573690
- Testing
- carboplatin, cisplatin, etoposide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Solid Tumors
A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
A dose escalating phase Ia-b clinical trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer. The objective is to study the safety and pharmacokinetics of AXL1717 and to define an appropriate Phase 2 dose…
- Trial name
- NCT01062620
- Testing
- AXL1717
- Where
- Sweden
- Volunteers
- 49 people
- Sponsor
- Axelar AB
Malignant Solid Tumor
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102.
- Trial name
- NCT01457118
- Testing
- NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2
- Where
- 7 sites in United States, Belgium
- Volunteers
- 27 people
- Sponsor
- Nektar Therapeutics
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation…
- Conditions
- Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02444741
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- M.D. Anderson Cancer Center
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Advanced Solid Tumors
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
- Trial name
- NCT01469052
- Testing
- AG-013736
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Solid Tumor, Unspecified, Adult
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
This proposal is a phase I, open-label study of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in patients with recurrent or metastatic, fibroblast activation protein-positive solid tumors.
- Trial name
- NCT05723640
- Testing
- 177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Hedgehog Pathway, Smoothened
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
- Conditions
- Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)
- Trial name
- NCT00670189
- Testing
- BMS-833923 (XL139)
- Where
- 3 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
RATIONALE: A computer-based survey and communication aid may help physicians and patients to communicate better and help make treatment decisions easier.
- Trial name
- NCT00244868
- Testing
- counseling intervention, educational intervention
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Fox Chase Cancer Center
Cancer
A Study of E7080 in Subjects With Solid Tumor
The purpose of this study is to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle) in subjects with solid tumors
- Trial name
- NCT01268293
- Testing
- E7080
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Eisai Co., Ltd.
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Solid Tumor
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
- Trial name
- NCT05547906
- Testing
- ASCA101
- Where
- 2 sites in United States, South Korea
- Volunteers
- 18 people
- Sponsor
- MetaFines
Leukemia, Lymphoma
Study of @neWorld: A Virtual Community for Children With Cancer
RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-to-read medical information, and chat with family members, medical staff…
- Conditions
- Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00070421
- Testing
- complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Sponsor
- Leap of Faith Technologies
Neoplasms
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients…
- Trial name
- NCT02952248
- Testing
- BI 754091
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Relapsed or Refractory Solid Tumors
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
The main purpose of this study is to evaluate the antitumor activity and safety of lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration.
- Trial name
- E7080-G000-231 (NCT04447755)
- Testing
- Lenvatinib
- Where
- 49 sites in United States, Argentina and 18 more
- Volunteers
- 127 people
- Sponsor
- Merck Sharp & Dohme LLC